If you have been reading about heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-19. Numbers and descriptions here follow the published literature rather than marketing material.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
An alternating copolymer has regular alternating A and B units, and is often described by the formula: -A-B-A-B-A-B-A-B-A-B-, or -(-A-B-)n-. The molar ratio of each monomer in the polymer is normally close to one, which happens when the reactivity ratios r1 and r2 are close to zero, as can be seen from the Mayo–Lewis equation. For example, in the free-radical copolymerization of styrene maleic anhydride copolymer, r1 = 0.097 and r2 = 0.001, so that most chains ending in styrene add a maleic anhydride unit, and almost all chains ending in maleic anhydride add a styrene unit. This leads to a predominantly alternating structure. A step-growth copolymer -(-A-A-B-B-)n- formed by the condensation of two bifunctional monomers A–A and B–B is in principle a perfectly alternating copolymer of these two monomers, but is usually considered as a homopolymer of the dimeric repeat unit A-A-B-B. An example is nylon 66 with repeat unit -OC-( CH2)4-CO-NH-(CH2)6-NH-, formed from a dicarboxylic acid monomer and a diamine monomer.
== HHV-6A and Infertility == A 2016 study showed that 43% of women with unexplained infertility tested positive for HHV-6A compared to 0% in the fertile control group. HHV-6A was found present in endometrial epithelial cells from women with unexplained infertility but not in their blood. In the context of infertility, this discovery underscores the importance of targeted testing for HHV-6A within the uterine environment, as the virus was not detected in the bloodstream of the affected individuals. Effective diagnosis, therefore, requires tests that are capable of distinguishing between active and latent HHV-6A infections specifically in endometrial tissue, highlighting the need for tissue-specific viral detection methods in assessing and managing infertility associated with HHV-6A. A 2018 study found 37% of women experiencing recurrent implantation failure after IVF/ET had HHV-6A in their endometrial biopsies, compared to 0% in control groups. A 2019 study confirmed the presence of HHV-6A infection in 40% of idiopathic infertile women. Identifying the effect of HHV-6A infection on endometrial immune status opens up a new perspectives on fertility care. It is possible to choose antiviral therapies and non-hormonal approaches for women with unexplained infertility characterized by HHV-6A to increase their pregnancy rate.
cytochemistry The branch of cell biology involving the detection and identification of various cellular structures and components, in particular their localization within cells, using techniques of biochemical analysis and visualization such as chemical staining and immunostaining, spectrophotometry and spectroscopy, radioautography, and electron microscopy.
Dual Recombinase technology can be used to induce multiple conditional mutations to study the diseases which manifest as a result of simultaneous mutations in multiple genes. Certain inteins have been identified which splice only at certain permissive temperatures, leading to improper protein synthesis and thus, loss-of-function mutations at other temperatures. Conditional mutations may also be used in genetic studies associated with ageing, as the expression can be changed after a certain time period in the organism's lifespan. Replication timing quantitative trait loci affects DNA replication.
Through the effective use of differential pumping; multiple vacuum stages separate by differential apertures (holes), the ions created in the argon plasma are, with the aid of various electrostatic focusing techniques, transmitted through the mass analyzer to the detector(s) and counted. Not only does this enable the analyst to radically increase sample throughput (amount of samples over time), but has also made it possible to do what is called "time resolved acquisition". Hyphenated techniques like Liquid Chromatography ICP-MS (LC-ICP-MS); Laser Ablation ICP-MS (LA-ICP-MS); Flow Injection ICP-MS (FIA-ICP-MS), etc. have benefited from this relatively new technology. It has stimulated the development of new tools for research including geochemistry and forensic chemistry; biochemistry and oceanography. Additionally, increases in sample throughput from dozens of samples a day to hundreds of samples a day have revolutionized environmental analysis, reducing costs. Fundamentally, this is all due to the fact that while the sample resides at environmental pressure, the analyzer and detector are at 1/10,000,000 of that same pressure during normal operation. An inductively coupled plasma (ICP) for spectrometry is sustained in a torch that consists of three concentric tubes, usually made of quartz, although the inner tube (injector) can be sapphire if hydrofluoric acid is being used. The end of this torch is placed inside an induction coil supplied with a radio-frequency electric current.
Sources: en.wikipedia.org
=== Pancreas === The human fetal pancreas begins to develop by the fourth week of gestation. Five weeks later, the pancreatic alpha and beta cells have begun to emerge. Reaching eight to ten weeks into development, the pancreas starts producing insulin, glucagon, somatostatin, and pancreatic polypeptide. During the early stages of fetal development, the number of pancreatic alpha cells outnumbers the number of pancreatic beta cells. The alpha cells reach their peak in the middle stage of gestation. From the middle stage until term, the beta cells continue to increase in number until they reach an approximate 1:1 ratio with the alpha cells. The insulin concentration within the fetal pancreas is 3.6 pmol/g at seven to ten weeks, which rises to 30 pmol/g at 16–25 weeks of gestation. Near term, the insulin concentration increases to 93 pmol/g. The endocrine cells have dispersed throughout the body within 10 weeks. At 31 weeks of development, the islets of Langerhans have differentiated. While the fetal pancreas has functional beta cells by 14 to 24 weeks of gestation, the amount of insulin that is released into the bloodstream is relatively low. In a study of pregnant women carrying fetuses in the mid-gestation and near term stages of development, the fetuses did not have an increase in plasma insulin levels in response to injections of high levels of glucose. In contrast to insulin, the fetal plasma glucagon levels are relatively high and continue to increase during development.
Hemostasis occurs when blood is present outside of the body or blood vessels. It is the innate response for the body to stop bleeding and loss of blood. During hemostasis three steps occur in a rapid sequence. Vascular spasm is the first response as the blood vessels constrict to allow less blood to be lost. In the second step, platelet plug formation, platelets stick together to form a temporary seal to cover the break in the vessel wall. The third and last step is called coagulation or blood clotting. Coagulation reinforces the platelet plug with fibrin threads that act as a "molecular glue". Platelets are a large factor in the hemostatic process. They allow for the creation of the "platelet plug" that forms almost directly after a blood vessel has been ruptured. Within seconds of a blood vessel's epithelial wall being disrupted, platelets begin to adhere to the sub-endothelium surface. It takes approximately sixty seconds until the first fibrin strands begin to intersperse among the wound. After several minutes the platelet plug is completely formed by fibrin. Hemostasis is maintained in the body via three mechanisms:
Austin held on to the WWF Championship until SummerSlam on August 22 when he lost it to Mankind in a triple threat match also featuring Triple H. in the two months that followed, Triple H would gain possession of the title. Austin would get his rematch at No Mercy on October 17 against Triple H, but Austin lost after The Rock accidentally struck him with a sledgehammer shot meant for Triple H. The three were advertised for a triple-threat match at Survivor Series on November 14, where Austin was run down by a car. The segment was to write him off television, with the neck injury suffered two years prior posing a real threat of early retirement, and was advised to undergo surgery. Austin would later describe this as "the worst storyline I was ever involved in". Austin made a one-off appearance at Backlash on April 30, 2000, attacking Triple H and Vince McMahon to help The Rock reclaim the WWF Championship. After Austin's official return at Unforgiven on September 24, Commissioner Mick Foley led an investigation to find out who ran Austin over, with the culprit revealed to be Rikishi. At No Mercy on October 22, Austin faced Rikishi in a No Holds Barred match, during which Austin attempted to run Rikishi down in a truck, but was prevented from doing so by officials, and the match was deemed a no contest; Austin was subsequently arrested. During a handicap match against Rikishi and Kurt Angle, Triple H came down with the apparent intention of teaming with Austin, only to hit Austin with a sledgehammer and reveal he had instructed Rikishi to run him over.
== History == DET was first synthesized and administered intramuscularly in a 60 mg dose by Stephen Szára in 1956. It was subsequently described in his material published in 1957. More systematic studies were reported later by Szara and colleagues and independently by Böszörményi and colleagues. Early research began as a search for "psychosis mimics" in psychiatry, then expanded into broader psychedelic and structure–activity studies. Selection of study subjects for some of these studies was criticized by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved) for its "oppressive research environment". For many years, based on early clinical reports and private communications, Shulgin maintained that DET exhibited psychoactive effects only when administered via parenteral routes. He eventually revised his view, ultimately acknowledging that the substance is also orally active. Initially, DET was not classified as a controlled substance, and some early clinical and experimental psychopharmacological research used it without scheduling restrictions. By the late 1960s and early 1970s, however, increasing regulatory attention led to tighter controls and this led to DET getting placed in Schedule I internationally by the Convention on Psychotropic Substances. Modern research on DET remains limited compared to dimethyltryptamine (DMT), due to its status as a controlled substance and the predominance of focus on other tryptamines with greater prevalence in traditional or clinical contexts.
Channa amari Dey et al., 2019 — likely a synonym of C. brunnea Channa amphibeus (McClelland, 1845) (Borna snakehead) Channa andrao Britz, 2013 Channa ara (Deraniyagala, 1945) Channa argus (Cantor, 1842) (northern snakehead) Channa aristonei Praveenraj, Thackeray, Singh, Uma, Moulitharan & Mukhim, 2020 Channa asiatica (Linnaeus, 1758) (small snakehead) Channa aurantimaculata Musikasinthorn, 2000 (orange-spotted snakehead) Channa aurantipectoralis Lalhlimpuia, Lalronunga & Lalramliana, 2016 Channa auroflammea Adamson, Britz and S. Lieng, 2019 Channa aurolineata (F. Day, 1870) Channa bankanensis (Bleeker, 1853) Channa baramensis (Steindachner, 1901) Channa barca (F. Hamilton, 1822) (barca snakehead) Channa bipuli Praveenraj, Uma, Moulitharan & Bleher, 2018 Channa bleheri Vierke, 1991 (rainbow snakehead) Channa brahmacharyi Chakraborty, Yardi & Mukherjee, 2020 Channa brunnea Praveenraj, Uma, Moulitharan & Kannan, 2019 Channa burmanica B. L. Chaudhuri, 1919 Channa coccinea Britz, H. H. Tan & Rüber, 2024 Channa cyanospilos (Bleeker, 1853) Channa diplogramma (F. Day, 1865) (Malabar snakehead) Channa gachua (F. Hamilton, 1822) (dwarf snakehead) Channa harcourtbutleri (Annandale, 1918) (Burmese snakehead) Channa hoaluensis Nguyen, 2011 Channa kelaartii (Günther, 1861) Channa limbata (Cuvier, 1831) Channa lipor Praveenraj, Uma, Moulitharan & Singh, 2019 Channa longistomata (Nguyen & Nguyen, 2012) Channa lucius (G. Cuvier, 1831) (forest snakehead) Channa maculata (Lacépède, 1801) (blotched snakehead) Channa marulioides (Bleeker, 1851) (emperor snakehead) Channa marulius (F.
Sources: en.wikipedia.org
== Development == Developed as a next generation aptamer technology, Optimer ligands were produced to improve the performance, manufacturability, and commercialisation of aptamers. Optimer ligands are selected via an automated, high throughput in vitro screening process. 3 distinct discovery platforms are integrated into the Optimer platform for optimized discovery according to target type. Starting from a diverse library of potential nucleic acid binders, the Optimer library is refined and enriched for sequences that have the required binding characteristics including affinity, specificity, cross reactivity, and buffer compatibility. The enriched Optimer population is subsequently screened to identify the best performing Optimer ligand sequence. Following selection of the appropriate sequence the identified Optimer undergoes a process to determine the minimum oligonucleotide fragment within this sequence that possesses the correct target-binding characteristics. The Optimer is trimmed to contain only this sequence, removing additional free non-target binding nucleotide bases. This reduces the molecular weight of the Optimer from 29 kDa to 5 kDa and increases the stability of the molecule through a reduction in entropy, as additional motion of the free nucleotides is removed.
According to the National Center for Education Statistics (NCES), between the academic years 2011–12 and 2018–19, the number of students aged three to twenty-one receiving special education under the Individuals with Disabilities Education Act (IDEA) increased from 6.4 million to 7.1 million, one third of whom suffered from a specific learning disability. After specific learning disabilities, the most common types of learning disorders included speech and language impairment (19%), autism (11%), and developmental delay (7%). Gains in the IQ scores of Americans first observed during the twentieth century—the Flynn effect—continued in the early twenty-first century, at least up until 2014. However, creativity scores, as measured by the Torrance Test of Creative Thinking, were in decline between the 1990s and the late 2000s. This is partly because American educations have chosen to emphasize standardization and test scores at the expense of encouraging creativity, and because American parents have been allowing their children little play time but a lot of screen time.
Sperm washing is the process in which individual sperm are separated from the semen. Washed sperm is used in artificial insemination using the intrauterine insemination (IUI) technique and in in vitro fertilization (IVF). It may also be used to decrease the risk of HIV transmission by an HIV-positive male, in which case the washed sperm is injected into a female using an artificial insemination technique. Sperm washing involves removing any mucus and non-motile sperm in the semen to improve the chances of fertilization and to extract certain disease-carrying material in the semen. Sperm washing is a standard procedure in infertility treatment. Once the fastest sperm have been isolated, before using them for artificial insemination or in vitro fertilization, it is important to confirm the absence of HIV virus in the sample. The sample obtained after washing is analysed, usually using the PCR technique, to check that there are no viral particles. If the result is negative, i.e. there is no virus, the sample is suitable for use in assisted reproduction treatments. Washed samples are usually free of the virus.
== Preparation == Phthalimide can be prepared by heating phthalic anhydride with alcoholic ammonia giving 95–97% yield. Alternatively, it may be prepared by treating the anhydride with ammonium carbonate or urea. It can also be produced by ammoxidation of o-xylene.
=== China === Gelatine dessert in China is defined as edible jelly-like food prepared from a mixture of water, sugar and gelling agent. The preparation processes include concocting, gelling, sterilising and packaging. In China, around 250 legal additives are allowed in gelatine desserts as gelling agents, colours, artificial sweeteners, emulsifiers and antioxidants. Gelatine desserts are classified into 5 categories according to the different flavouring substances they contain. Five types of flavouring substance include artificial fruit flavoured type (less than 15% of natural fruit juice), natural fruit flavoured type (above 15% of natural fruit juice), natural flavoured with fruit pulp type and dairy type products, which includes dairy ingredients. The last type ("others") summarises gelatine desserts not mentioned above. It is typically sold in single-serving plastic cups or plastic food bags.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.